The Centers for Medicare & Medicaid Services May 12 released draft guidance for the third round of negotiations for the Medicare Drug Price Negotiation Program. The guidance includes policies incorporating drugs payable under Medicare Part B into the program for the first time and is soliciting comments on how to facilitate access to any negotiated maximum fair price for Part B drugs. The guidance also explains how CMS would choose certain drugs for renegotiation that were initially negotiated for applicability in 2026 and 2027. Additionally, it includes clarifications on how participating drug manufacturers would make negotiated MFPs available in 2026 and 2027 and extends those policies to drugs covered under Part D in 2028. 
 
CMS is accepting comments on the draft guidance until 11:59 p.m. PT June 26. 

Headline
The Centers for Medicare & Medicaid Services Nov. 16 issued a proposed rule on program integrity oversight in Medicare, Medicaid, the Children’s Health…
Headline
The Centers for Medicare & Medicaid Services Nov. 5 published a final rule to codify the Medicare Drug Price Negotiation Program beginning in 2029. The…
Headline
The estimated average monthly premium for Medicare Part D stand-alone prescription drug plans is $51 for 2027, a 50% increase from $34 in 2026, for enrollees…
Headline
The Department of Labor Oct. 29 finalized a rule designed to improve transparency of fees collected by pharmacy benefit managers. The rule requires PBMs to…
Headline
The Centers for Medicare & Medicaid Services released a proposed rule Oct. 16 seeking to codify regulations that will improve the accuracy of Medicare…
Headline
The Centers for Medicare & Medicaid Services announced that it will exercise enforcement discretion for inpatient rehabilitation facility admissions from…